Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05952141 · ClinicalTrials.gov registry record · NA
Strategies to Close the Gap From Cervical Cancer Diagnosis to Treatment in Botswana
A NA study of Cervical Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 680
- Enrollment target
- 3
- Study locations
NCT05952141: Recruiting NA study of Cervical Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
NCT05952141 is a NA study of Cervical Cancer that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 680 participants, above the 566-participant average among 144 other Cervical Cancer trials with a reported enrollment target (20% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05952141, a NA study of Cervical Cancer, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 680 participants
- Enrollment target
- 3
- Study locations
Study Summary
Investigators will test the effectiveness of adaptive strategies on timely adoption of cervical cancer treatment in Botswana using a pragmatic trial design.
Primary Outcome
Defined as the initiation of cervical cancer treatment within 90 days of randomization.
Conditions Studied
Interventions
- BEHAVIORAL Clinic Outreach
- BEHAVIORAL Enhanced Outreach
- BEHAVIORAL Low-Touch Strategy
- BEHAVIORAL High-Touch Strategy
Study Locations (3)
Pennsylvania
- University of Pennsylvania - Philadelphia
North-East District
- Nyangabgwe Referral Hospital - Francistown
Other
- Princess Marina Hospital - Gaborone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 680 participants |
| Start Date | 2023-09-01 |
| Est. Completion | 2027-08-31 |
| Phase | NA |
What NCT05952141 shows while recruiting
NCT05952141 is an interventional study that assigns participants to a tested intervention. The registered 680 participants enrollment target is mid-sized for trials with a published cap, above the 566-participant average among 144 other Cervical Cancer trials with a reported enrollment target (20% higher).
The record links to 1 condition, with Cervical Cancer appearing as the primary indexed condition, and to 4 interventions - of which Clinic Outreach is the first listed.
NCT05952141 reports a single indexed study location in Pennsylvania, North-East District, Other.
Frequently Asked Questions
What is clinical trial NCT05952141 about?
NCT05952141 is a clinical study titled "Strategies to Close the Gap From Cervical Cancer Diagnosis to Treatment in Botswana". Investigators will test the effectiveness of adaptive strategies on timely adoption of cervical cancer treatment in Botswana using a pragmatic trial design.
What is the current status of trial NCT05952141?
This trial is currently recruiting. It is a NA study. The enrollment target is 680 participants. The study started on 2023-09-01. Estimated completion is 2027-08-31.
What conditions does trial NCT05952141 study?
This clinical trial studies the following conditions: Cervical Cancer.
What interventions are being tested in trial NCT05952141?
The interventions under investigation include: Clinic Outreach (BEHAVIORAL), Enhanced Outreach (BEHAVIORAL), Low-Touch Strategy (BEHAVIORAL), High-Touch Strategy (BEHAVIORAL).
Who is sponsoring clinical trial NCT05952141?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05952141 being conducted?
This trial has 3 study locations across Pennsylvania, North-East District. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05952141's enrollment target sits among peer trials
680 22nd of 144 higher than 123 of 144 other Cervical Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
ASk Questions in GYnecologic Oncology (ASQ-GYO)
RECRUITING · NA
-
ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Self-Collection of the Pap Smear as Agency: A Novel Way to Improve Refractory Low Cervical Cancer Screening Rates in Rural Alabama
RECRUITING · NA
-
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03501706 · 680 participants · NA
An Assessment of Cognitive Improvement Training Among Mid-life Individuals
- NCT05626452 · 680 participants · NA
PrEP Optimization Among Women to Enhance Retention and Uptake
- NCT05753748 · 680 participants · NA
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
- NCT06112314 · 680 participants · Phase 3
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI